GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | EP300 | decreases expression | EXP | | 6480464 | CTD | Doxorubicin results in decreased expression of EP300 mRNA; Doxorubicin results in decreased expression of EP300 protein | PMID:10344722 PMID:17498666 | EP300 | multiple interactions | EXP | | 6480464 | CTD | [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Doxorubicin; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Doxorubicin; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Doxorubicin]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Doxorubicin] | PMID:19047049 | EP300 | decreases expression | ISO | Ep300 (Mus musculus) | 6480464 | CTD | Doxorubicin results in decreased expression of EP300 protein | PMID:14975762 | EP300 | decreases expression | ISO | Ep300 (Rattus norvegicus) | 6480464 | CTD | Doxorubicin results in decreased expression of EP300 mRNA; Doxorubicin results in decreased expression of EP300 protein | PMID:11073966 PMID:15767673 PMID:28865727 | EP300 | decreases response to substance | ISO | Ep300 (Mus musculus) | 6480464 | CTD | EP300 protein results in decreased susceptibility to Doxorubicin | PMID:14975762 | EP300 | increases degradation | ISO | Ep300 (Rattus norvegicus) | 6480464 | CTD | Doxorubicin results in increased degradation of EP300 protein | PMID:11073966 | EP300 | increases expression | ISO | Ep300 (Mus musculus) | 6480464 | CTD | Doxorubicin results in increased expression of EP300 protein | PMID:25665036 | EP300 | multiple interactions | ISO | Ep300 (Mus musculus) | 6480464 | CTD | 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [resveratrol inhibits the reaction [Doxorubicin results in increased expression of EP300 protein]]; resveratrol inhibits the reaction [Doxorubicin results in increased expression of EP300 protein]; sirtinol inhibits the reaction [resveratrol inhibits the reaction [Doxorubicin results in increased expression of EP300 protein]] | PMID:25665036 | EP300 | multiple interactions | ISO | Ep300 (Rattus norvegicus) | 6480464 | CTD | 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Doxorubicin results in decreased expression of EP300 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Doxorubicin results in increased degradation of EP300 protein]; [1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine co-treated with Doxorubicin] results in increased expression of EP300 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Doxorubicin results in increased degradation of EP300 protein]; Doxorubicin results in increased phosphorylation of and results in increased degradation of EP300 protein; EP300 inhibits the reaction [Doxorubicin results in decreased expression of MEF2C mRNA]; SB 203580 inhibits the reaction [Doxorubicin results in decreased expression of EP300 protein] | PMID:11073966 PMID:15767673 | | ||||||||||||||||||||||
| Go Back to source page | Continue to Ontology report |